Active, Not Recruiting
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: - The characteristics and treatment sequence of patients treated with nivolumab - The effectiveness of nivolumab treatment - The safety profile of nivolumab - Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab - The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Pathologically confirmed diagnosis of advanced NSCLC - Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label - Previously treated with at least one prior chemotherapy- containing regimen Exclusion Criteria: - Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs - Participants with a diagnosis of another primary cancer within the past five years - Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study Other protocol-defined inclusion/exclusion criteria apply
Cohort 1
Cohort 2
Cohort 3
